Beneski Benjamin Machinas 4

What Happened
Beneski Benjamin Machinas, SVP and Chief Technical Officer of Allogene Therapeutics, sold 4,835 shares on 2026-03-16 in open-market transactions for a total of approximately $11,942 (weighted average price reported as $2.47). The filing indicates this was a mandated "sell-to-cover" to satisfy tax withholding related to the vesting of restricted stock units, not a discretionary sale.

Key Details

• Transaction date: 2026-03-16; Form 4 filed: 2026-03-18 (timely filing).
• Shares sold: 4,835; reported weighted average price: $2.47; price range across transactions: $2.46–$2.47.
• Total proceeds reported: ~$11,942.
• Footnote F1: Sale was required by the issuer’s equity plan to cover tax withholding for RSU vesting — not a voluntary trade by the insider.
• Footnote F2: Price is a weighted average; the filer will provide breakdown of shares sold at each price upon request.
• Shares owned after the transaction: not provided in the supplied data.

Context
Sell-to-cover transactions are a common administrative step when RSUs vest and generally reflect tax withholding mechanics rather than a signal about an insider’s view of the company. The filing appears timely (filed two days after the transaction).